PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

J Thorac Oncol. 2017 May;12(5):778-781. doi: 10.1016/j.jtho.2017.03.018.

¹ Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-University Grenoble Alpes, Grenoble, France. Electronic address: sylvie.lantuejoul@lyon.unicancer.fr.
² Department of Biopathology-Register MESONAT, Cancer Center of Léon Bérard, Lyon, France; INSERM UMR 1086, Cancers & Preventions, University Caen Basse-Normandie, Caen, France.
³ Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France.
⁴ University Lille, CHU Lille, MESOCLIN, Lille, France.
⁵ Department of Biopathology, National referent center MESOPATH-Base National Clinicobiologic Databasis MESOBANK Register multicenter MESONAT-Sante public cancer center of Léon Bérard, Lyon, France.

No abstract available

Publication types